Drug
Ft576
Ft576: highest development phase Phase 1, developed by Fate Therapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Fate Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| FT576 (Allogenic CAR NK cells with BCMA expression) NCT05182073 | Phase 1 | Multiple Myeloma |
Latest
No recent events.
Follow Ft576 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.